Pipeline > Overview
ProtAffin is developing a portfolio of glycan-binding decoy proteins derived from our CellJammer® discovery platform. The initial focus is on chemokines for chronic and acute inflammatory conditions and on the clinical validation of glycan-binding decoy proteins for inflammation in respiratory medicine. Significant potential also exists in immune-inflammatory, neuro-inflammatory indications and oncology.